Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com

Dow Jones

03/09

By George Glover

Hims & Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with Novo Nordisk, the Danish drugmaker that sells Ozempic and Wegovy.

Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&P 500 slumped 0.8% after the Iran war triggered a surge in oil prices.

Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter.

Novo and Hims didn't immediately respond to requests for comment from Barron's.

Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy.

Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called "knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process."

The report of the truce comes at a time when both stocks have been struggling.

Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall.

Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny.

Write to George Glover at george.glover@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 09, 2026 06:33 ET (10:33 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618605647"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618605647\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618605647?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618605647","market":"fut","top_or_hot":-1,"title":"Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Hims &amp; Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the Danish drugmaker that sells Ozempic and Wegovy. \n</p>\n<p>\n  Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&amp;P 500 slumped 0.8% after the Iran war triggered a surge in oil prices. \n</p>\n<p>\n  Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter. \n</p>\n<p>\n  Novo and Hims didn't immediately respond to requests for comment from Barron's. \n</p>\n<p>\n  Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy. \n</p>\n<p>\n  Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\" \n</p>\n<p>\n  The report of the truce comes at a time when both stocks have been struggling. \n</p>\n<p>\n  Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall. \n</p>\n<p>\n  Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says. -- Barrons.com\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-09 18:33</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Hims &amp; Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the Danish drugmaker that sells Ozempic and Wegovy. \n</p>\n<p>\n  Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&amp;P 500 slumped 0.8% after the Iran war triggered a surge in oil prices. \n</p>\n<p>\n  Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter. \n</p>\n<p>\n  Novo and Hims didn't immediately respond to requests for comment from Barron's. \n</p>\n<p>\n  Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy. \n</p>\n<p>\n  Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\" \n</p>\n<p>\n  The report of the truce comes at a time when both stocks have been struggling. \n</p>\n<p>\n  Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall. \n</p>\n<p>\n  Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618605647","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618605647","pubTimestamp":1773052380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with Novo Nordisk, the Danish drugmaker that sells Ozempic and Wegovy.Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&P 500 slumped 0.8% after the Iran war triggered a surge in oil prices.Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter.Novo and Hims didn't immediately respond to requests for comment from Barron's.Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy.Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\". ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4196":"保健护理服务","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","BK4585":"ETF&股票定投概念","HIMY":"Defiance Leveraged Long + Income HIMS ETF","NVOH":"Novo Nordisk A/S B Shares ADRhedged","HMYY":"GraniteShares YieldBoost HIMS ETF","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVOX":"2倍做多NVO ETF-Defiance","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HIMS":"Hims & Hers Health Inc.","NVO":"诺和诺德","BK4588":"碎股","HIYY":"YieldMax HIMS Option Income Strategy ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"Hims&Hers股价飙升54%。报道称，该公司已与诺和诺德达成休战协议。——Barrons.com","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMYY":0.6,"HIMY":0.6,"HIMS":1.97,"NVOX":0.6,"NVO":1.95,"HIMZ":0.6,"NVOH":0.6,"HIYY":0.6},"content_text":"By George Glover \n\n\n  Hims & Hers Health stock was rallying on Monday after a report said that the telehealth platform had struck a deal to end its battle with Novo Nordisk, the Danish drugmaker that sells Ozempic and Wegovy. \n\n\n  Hims shares soared 53.6% to $24.19 ahead of the opening bell. Novo's American depositary receipts climbed 0.7%. Futures tracking the S&P 500 slumped 0.8% after the Iran war triggered a surge in oil prices. \n\n\n  Novo has agreed to sell its weight-loss drugs on Hims' platform and the partnership could be announced as soon as Monday, Bloomberg reported, citing a person familiar with the matter. \n\n\n  Novo and Hims didn't immediately respond to requests for comment from Barron's. \n\n\n  Hims in February canceled the launch of a copycat version of Novo's weight-loss medication Wegovy. \n\n\n  Novo then said it had filed a lawsuit against Hims for selling what Novo's general counsel John Kuckelman called \"knockoff versions of Wegovy and Ozempic that evade the Food and Drug Administration's gold standard review process.\" \n\n\n  The report of the truce comes at a time when both stocks have been struggling. \n\n\n  Novo's ADRs are down 24% in 2026, slumping after the drugmaker issued a dismal outlook for the current year, saying it expects sales to fall. \n\n\n  Hims has tumbled 52% as investors fret about Novo's lawsuit and heightened regulatory scrutiny. \n\n\n  Write to George Glover at george.glover@dowjones.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:33 ET (10:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}